Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein (original) (raw)
Conformation of the HIV-1 Gag Protein in Solution
Siddhartha Datta
Journal of Molecular Biology, 2007
View PDFchevron_right
An extended CCR5-ECL2 peptide forms a helix that binds HIV-1 gp120 through non-specific hydrophobic interactions
Fred Naider
FEBS Journal, 2015
View PDFchevron_right
Solution structure of peptides from HIV-1 Vpr protein that cause membrane permeabilization and growth arrest
Ian Macreadie
Journal of Peptide Science, 1998
View PDFchevron_right
Indinavir plasma protein binding in HIV-1-infected adults
Rory Remmel
AIDS, 2000
View PDFchevron_right
Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins
Bernard Gay
Journal of General Virology, 1998
View PDFchevron_right
Three-Dimensional Structure of HIV-1 Rev Protein Filaments
Benes Trus
Journal of Structural Biology, 1998
View PDFchevron_right
Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41
Adam Finnefrock
mAbs, 2009
View PDFchevron_right
Mapping the anatomy of the immunodominant domain of the human immunodeficiency virus gp41 transmembrane protein: peptide conformation analysis using …
Nuria Assa-Munt
Journal of …, 1991
View PDFchevron_right
Identification of the gC1qR sites for the HIV-1 viral envelope protein gp41 and the HCV core protein: Implications in viral-specific pathogenesis and therapy
Christopher Valentino
Molecular Immunology, 2016
View PDFchevron_right
Interaction between HIV1 Rev and Integrase Proteins: A BASIS FOR THE DEVELOPMENT OF ANTI-HIV PEPTIDES
Abraham Loyter
Journal of Biological Chemistry, 2007
View PDFchevron_right
Activation of gp120 of human immunodeficiency virus by their V3 loop-derived peptides
俊夫 服部
Biochemical and Biophysical Research Communications, 2002
View PDFchevron_right
Cytopathic Mechanisms of HIV-1
Joshua Costin
Virology Journal, 2007
View PDFchevron_right
HIV-based lentiviral vectors: Origin and sequence differences
Anna Isabel Garcia Alvarado
Molecular Therapy - Methods & Clinical Development, 2021
View PDFchevron_right
The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function
Nigel Dimmock
Virology, 2005
View PDFchevron_right
HIV-based lentiviral vectors for anti-HIV gene therapy
Ben Berkhout
Future Virology, 2010
View PDFchevron_right
A Cell-penetrating Helical Peptide as a Potential HIV-1 Inhibitor
Xiaohe Tong
Journal of Molecular Biology, 2008
View PDFchevron_right
Concentration-dependent differential induction of necrosis or apoptosis by HIV-1 lytic peptide 1
Joshua Costin
Peptides, 1999
View PDFchevron_right
Anti-HIV Activity of Multibranched Peptide Constructs Derived either from the Cleavage Sequence or from the Transmembrane Domain (gp41) of the Human Immunodeficiency Virus Type 1 Envelope
kamel mabrouk
Virology, 1996
View PDFchevron_right
A GxxxG-like Motif within HIV-1 Fusion Peptide Is Critical to Its Immunosuppressant Activity, Structure, and Interaction with the Transmembrane Domain of the T-cell Receptor
Omri Faingold
Journal of Biological Chemistry, 2012
View PDFchevron_right
Helix-Loop-Helix Motif in HIV-1 Rev
Hubert Gstach
Biochemistry, 1994
View PDFchevron_right
AVPpred: collection and prediction of highly effective antiviral peptides
Manoj Kumar
2012
View PDFchevron_right
Modification of FP-HIV activity by peptide sequences of GB virus C: A biophysical approach
Victoria Girona
Biochimica Et Biophysica Acta-Biomembranes, 2014
View PDFchevron_right
Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site
Robert Harrison
European Journal of Biochemistry, 2004
View PDFchevron_right
Broad activation of latent HIV-1 in vivo
Ole Søgaard
Nature Communications, 2016
View PDFchevron_right
Mode of Action of an Antiviral Peptide from HIV-1
Yossef Kliger
Journal of Biological Chemistry, 2001
View PDFchevron_right
HIV-1 Replication Is Inhibited by a Pseudo-substrate Peptide That Blocks Tat Transactivation
Takashi Okamoto
Virology, 2000
View PDFchevron_right
Large Changes in the CRAC Segment of gp41 of HIV Do Not Destroy Fusion Activity if the Segment Interacts with Cholesterol
Annick Thomas
Biochemistry, 2008
View PDFchevron_right
The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20
Ding-kwo Chang
Protein …, 2003
View PDFchevron_right
HIV-1 entry – an expanding portal for drug discovery
Nicholas Meanwell
Drug Discovery Today, 2000
View PDFchevron_right
Murine retroviral vector that induces long-term expression of HIV-1 envelope protein
Damian Purcell
Journal of Virological Methods, 1994
View PDFchevron_right
Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions
Vinay Pathak
Virology, 2007
View PDFchevron_right
Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages
kamel mabrouk
Peptides 1994, 1995
View PDFchevron_right
The L–VP35 and L–L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals
Kristina Brauburger
Virology, 2013
View PDFchevron_right
Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease
Robert Harrison
Protein Engineering Design and Selection, 2000
View PDFchevron_right
A Binding Pocket for a Small Molecule Inhibitor of HIV-1 Entry Within the Transmembrane Helices of CCR5
Steven Lin X
Proceedings of the …, 2000
View PDFchevron_right